Corp /De/ Celgene Sells 16,875 Shares of Crispr Therapeutics AG (CRSP) Stock

Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 16,875 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $18.06, for a total value of $304,762.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total value of $172,800.00.

Shares of Crispr Therapeutics AG (CRSP) traded up $0.01 during trading on Thursday, reaching $18.53. The company had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.77) EPS. analysts anticipate that Crispr Therapeutics AG will post -2.46 earnings per share for the current year.

A number of equities analysts have recently issued reports on CRSP shares. Barclays reiterated a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a report on Friday, September 8th. SunTrust Banks reissued a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Chardan Capital reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. Finally, BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $22.38.

Institutional investors have recently modified their holdings of the company. Allianz Asset Management GmbH purchased a new position in Crispr Therapeutics in the third quarter worth about $2,384,000. Granahan Investment Management Inc. MA grew its position in Crispr Therapeutics by 51.7% in the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after acquiring an additional 89,839 shares in the last quarter. Credit Suisse AG purchased a new position in Crispr Therapeutics in the first quarter worth about $1,742,000. Adams Street Partners LLC purchased a new position in Crispr Therapeutics in the third quarter worth about $1,019,000. Finally, Hershey Trust Co. purchased a new position in Crispr Therapeutics in the third quarter worth about $768,000. Hedge funds and other institutional investors own 24.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Corp /De/ Celgene Sells 16,875 Shares of Crispr Therapeutics AG (CRSP) Stock” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2017/12/07/corp-de-celgene-sells-16875-shares-of-crispr-therapeutics-ag-crsp-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply